PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07C 233/78, A61K 31/165 | A1

(11) International Publication Number: **WO 98/43947**

(43) International Publication Date: 8 October 1998 (08.10.98)

(21) International Application Number: PCT/EP98/01913

(22) International Filing Date: 24 March 1998 (24.03.98)

(30) Priority Data:
9706376.2 27 March 1997 (27.03.97) GB

(71) Applicant *(for all designated States except US)*: SMITHKLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: SLATER, Graham, Ralph [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Part South, Third Avenue, Harlow, Essex CM19 5AW (GB). WESTLAKE, Paul, Jeffrey [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Part South, Third Avenue, Harlow, Essex CM19 5AW (GB).

(74) Agent: RUTTER, Keith; SmithKline Beecham plc, Corporate Intellectual Property, Two New Horizons Court, Brentford, Middlesex, TW8 9EP (GB).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: NITRO–BENZAMIDE USEFUL AS ANTI–ARRHYTHMIC AGENT

(57) Abstract

Hydrated N–[3–[[2–(3,4–dimethoxyphenyl)ethyl]amino]propyl]–4–nitro benzamide hydrochloride characterised in that it: (i) comprises water in the range of from 1.7 to 2.4 molar equivalents; and/or (ii) has a melting point above 145 °C and/or, (iii) provides an infra red spectrum containing peaks at 3510, 3342, 3076, 1665, 1598, 1343, 1330, 1216 and 801 cm^{-1}; and/or (iv) provides a solid state nuclear magnetic resonance spectrum containing chemical shifts substantially as represented in Table I; and/or (v) provides an X–ray powder refraction (XRPD) pattern substantially as represented in Table II; a process for preparing such a compound, a pharmaceutical composition comprising such a compound and the use of such a compound in medicine.